Literature DB >> 27799389

Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands.

Connie G M Erkens1, Erika Slump2, Maurits Verhagen3, Henrieke Schimmel2, Frank Cobelens4,5,6, Susan van den Hof4,5,6.   

Abstract

Diagnosis and preventive treatment of latent tuberculosis infection (LTBI) among high-risk groups is recommended to achieve tuberculosis (TB) elimination in low-incidence countries.We studied TB incidence rates among those notified with LTBI in the Netherlands from 2005 to 2013 and analysed associated risk factors. We stratified analyses by target group for screening, and by initiation and completion of preventive treatment.The incidence for those completing, stopping and not receiving preventive treatment was 187, 436 and 355 per 100 000 person-years for contacts of TB patients, respectively, and 63, 96 and 110 per 100 000 person-years for other target groups. The rate ratio for TB development among contacts compared to other target groups was 3.1 (95% CI 2.0-4.9). In both groups, incidence was highest in the first year after diagnosis. Independent factors associated with progression to TB among contacts were age <5 years and stopping preventive treatment within 28 days compared to those not receiving preventive treatment. Among other target groups, being foreign born was the only risk factor associated with the risk of developing TB.We conclude that the epidemiological impact of preventive treatment is highest in contacts of TB patients and limited in other target groups for LTBI management in the Netherlands.
Copyright ©ERS 2016.

Entities:  

Mesh:

Year:  2016        PMID: 27799389     DOI: 10.1183/13993003.01157-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

1.  Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings.

Authors:  Marc Lipman; Mahdad Noursadeghi; Ibrahim Abubakar; Rishi K Gupta; Claire J Calderwood; Alexei Yavlinsky; Maria Krutikov; Matteo Quartagno; Maximilian C Aichelburg; Neus Altet; Roland Diel; Claudia C Dobler; Jose Dominguez; Joseph S Doyle; Connie Erkens; Steffen Geis; Pranabashis Haldar; Anja M Hauri; Thomas Hermansen; James C Johnston; Christoph Lange; Berit Lange; Frank van Leth; Laura Muñoz; Christine Roder; Kamila Romanowski; David Roth; Martina Sester; Rosa Sloot; Giovanni Sotgiu; Gerrit Woltmann; Takashi Yoshiyama; Jean-Pierre Zellweger; Dominik Zenner; Robert W Aldridge; Andrew Copas; Molebogeng X Rangaka
Journal:  Nat Med       Date:  2020-10-19       Impact factor: 53.440

Review 2.  Recent Advances in Host-Directed Therapies for Tuberculosis and Malaria.

Authors:  Kely C Matteucci; André A S Correa; Diego L Costa
Journal:  Front Cell Infect Microbiol       Date:  2022-05-20       Impact factor: 6.073

3.  A highly transmissible tuberculosis outbreak: the importance of bars.

Authors:  P Godoy; M Alsedà; M Falguera; T Puig; P Bach; M Monrabà; A Manonelles
Journal:  Epidemiol Infect       Date:  2017-11-28       Impact factor: 4.434

4.  Policy and practice of programmatic management of latent tuberculosis infection in The Netherlands.

Authors:  Gerard de Vries; Rob van Hest; Marleen Bakker; Connie Erkens; Susan van den Hof; Wieneke Meijer; Karen Oud; Erika Slump; Jaap van Dissel
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2017-03-18

5.  Evaluation of QuantiFERON-TB Gold Plus for Predicting Incident Tuberculosis among Recent Contacts: A Prospective Cohort Study.

Authors:  Rishi K Gupta; Heinke Kunst; Marc Lipman; Mahdad Noursadeghi; Charlotte Jackson; Jo Southern; Ambreen Imran; Stefan Lozewicz; Ibrahim Abubakar
Journal:  Ann Am Thorac Soc       Date:  2020-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.